Skip to main content

Table 4 Baseline and relapse levels of ALT and HBV DNA in patients with relapse

From: Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative

No.

NUCs

HBV DNA - log10 IU/mL

ALT - ULN

Retreat

  

Baseline

Relapse

Baseline

Relapse

 

1

LAM

7.70

3.39

1.67

1.02

ETV

2

LAM

7.67

3.51

3.88

1.45

ETV

3

ADV

3.91

3.35

1.43

0.57

ADV

4

ADV

4.14

3.74

2.71

0.74

ADV

5

ADV

5.88

3.41

1.48

0.36

ADV

6

ADV

5.42

5.71

7.33

4.90

ADV

7

ADV

7.71

3.41

8.00

0.83

ADV

8

ADV

3.87

3.44

1.26

1.00

ADV

9

ADV

6.32

3.43

1.31

0.98

ADV

10

ADV

5.39

3.77

1.05

0.36

ADV

11

ADV

5.86

4.06

6.69

1.21

ADV

12

ADV

3.33

3.39

1.38

0.90

ADV

13

ADV

6.37

3.60

5.07

1.31

ADV

14

ADV

5.68

4.51

6.57

1.57

ADV

15

ADV

4.42

4.15

1.08

0.98

ADV

16

ADV

4.68

3.31

1.32

0.17

ADV

17

ADV

7.39

4.06

3.55

0.60

ADV

18

ETV

4.55

5.22

2.74

1.07

ETV

19

ETV

5.63

3.68

1.19

1.29

ETV

  1. LAM, lamivudine; ADV, adefovir; ETV, entecavir.